{"name":"Aiwu Ruth He, MD","slug":"aiwu-ruth-he-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Sylatron","genericName":"Sylatron","slug":"sylatron","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"Sylatron","genericName":"Sylatron","slug":"sylatron","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPdFFPUjRlWllVRDVleEtKMmtXWTVheHBYSlNyMUxwUmszbWd2NTZiRUNtbFotUWRwak9VdVhzVlBaTVRhb1p1ZVgtcmFPdmNKSTVYVnE0Qm9CeHFtRlRTa0VfaXZ6el9kU2FlNF9IUWR0bGt2TzdKbWJzNG5iSW1XWnVpMTk3RzF2SHRYVGRmek1Odm9fb3huSzlTUW9YLU1ZY1gyYXhMYVZrRFdPWmh3TFc2WnJIR18ydGJoREc2djJ2MEc1?oc=5","date":"2025-04-14","type":"regulatory","source":"Pharmaceutical Executive","summary":"FDA Grants Full Approval to Opdivo Plus Yervoy Regimen for Unresectable or Metastatic Hepatocellular Carcinoma - Pharmaceutical Executive","headline":"FDA Grants Full Approval to Opdivo Plus Yervoy Regimen for Unresectable or Metastatic Hepatocellular Carcinoma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNTGFZY3JqUURHODFIeWhac0FOQmd0VDExdC1PLUhfSlpVX2UwaERPQnZ0R3VYLWsybkhNZzZGdGxRWW1KRjNsdXpMQTNGbnlMMFdEVkxNT3RfeWp3eVBCa3lxN3RPeFdBSnVkVkJnMm5HeHBiYUhEOERnV2NfajRNMENaU1BacTRvQnpTamE3c2tsRnBvb2I3T05kTFhlY3V6YTJuMnJZWWh5QVFSa1VfaGE3UXNFM1pTTHgtMEpGVHRxeF93SWlxMg?oc=5","date":"2025-03-12","type":"pipeline","source":"Cancer Therapy Advisor","summary":"Treatment Strategies for Advanced Hepatocellular Carcinoma From ASCO GI 2025 - Cancer Therapy Advisor","headline":"Treatment Strategies for Advanced Hepatocellular Carcinoma From ASCO GI 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOTnlScFBPbjhTMmxSSldSekQ3Y0tkWVBuQWhtWUM2VkQzVmM0Q1BpVjdKY3BYRnZVa1RFWksxY2pNSkVQT1dlN05FN2lHNGJsT2E2eUtzaU0tTXphVXY2WnhqWktxZ2Uwc2hBTV9ZdzYxZEhackMzU2ZfUzN2UFVvN0g3cGdOeW5abmpNVlg5N094a2ctT1JwaGVRM0NnZzMtcGNnN1VBREJyci1UX2JPOXV4dUlZazZXaEpuczZCc1l3YW94WERyeUtjYlIxWWJDME9PTGFMMjk?oc=5","date":"2024-05-27","type":"trial","source":"ajmc.com","summary":"Aiwu Ruth He, MD, PhD, Discusses 3-Year Survival Data for Durvalumab Plus Chemo in Biliary Tract Cancer, Other Advances - ajmc.com","headline":"Aiwu Ruth He, MD, PhD, Discusses 3-Year Survival Data for Durvalumab Plus Chemo in Biliary Tract Cancer, Other Advances","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxONS1TdVB4b1FmTHlhSzBIQ0twRGVzTnYzdnhnYzVwUUdfUC1ZYW03V1dYRnVkWndreVJXSG14QnZYWkZFUEJhclRrOEZKYmpTNEU0dGdJMTlYblRiUUU2MWJDbVZYdlVleGV2STE5b3JFZm5pSTNiTV80RF9vdUZXWHJOY2xheFRqVDdhS2pYSTlQTGExTjB3LXZsYXgtSjdQRktQc0F1dUlRTmRoMWN5dVVrWWgtdWZIaWdpSEZhWUIxRGtiMlJKRWdpam9LdFBUcHE5RA?oc=5","date":"2023-01-24","type":"pipeline","source":"Healio","summary":"Use of antibiotics safe during durvalumab-based treatment for biliary tract cancer - Healio","headline":"Use of antibiotics safe during durvalumab-based treatment for biliary tract cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1COVltal8xWC1nM1cwWFhvdTdWNzNpV3pYNHNOeUxfcUxzcnJCQW9aNm9XXzRTVHpxUzVOcDFWRFBYTl9jNERmSERhMnlVc0YxZzE4a1p6cFhYRUZHRW55ODR4Y3JDUEk?oc=5","date":"2022-06-01","type":"pipeline","source":"NEJM Evidence","summary":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer - NEJM Evidence","headline":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}